1 / 16

Inhaled Colistin Use in Adults With Hospital-Acquired and Ventilator-Associated Pneumonia

Inhaled Colistin Use in Adults With Hospital-Acquired and Ventilator-Associated Pneumonia. Samantha L Gauthier, Pharm.D . PGY-1 Pharmacy Resident Unity Health – White County Medical Center. Disclosure. I have nothing to disclose

Rita
Télécharger la présentation

Inhaled Colistin Use in Adults With Hospital-Acquired and Ventilator-Associated Pneumonia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inhaled Colistin Use in Adults With Hospital-Acquired and Ventilator-Associated Pneumonia Samantha L Gauthier, Pharm.D. PGY-1 Pharmacy Resident Unity Health – White County Medical Center

  2. Disclosure • I have nothing to disclose • Neither I, nor my spouse, have at present and/or have had within the past 12 months a relevant financial relationship with a commercial interest

  3. Pharmacist Objectives • Differentiate between available formulations • Compare doses of inhaled colistimethate, considering formulations and patient prognosis/severity • Identify patients that qualify to receive inhaled colistimethateper the 2016 IDSA and ATS HAP/VAP guidelines • Summarize appropriate use of inhaled colistimethateper the 2016 IDSA and ATS HAP/VAP guidelines

  4. Technician Objectives • Identify which patients should receive inhaled colistimethate per the 2016 IDSA and ATS HAP/VAP guidelines. • Compare the different formulations of colistimethate. • Discuss the dosing techniques for colistimethate based on the patient’s severity.

  5. Abbreviations • HAP: hospital-acquired pneumonia • VAP: ventilator-associated pneumonia • CMS: colistimethate sodium • CBA: colistin base activity • GNB: gram-negative bacilli • AG: aminoglycosides • MDR: multi-drug resistant

  6. Outline • Background • Dosing/Administration • Patient Qualifications • Recommendations per IDSA/ATS • Summary

  7. Background • Class: polymyxin • MOA: disruption of outer cell membrane • Bactericidal • Spectrum of Activity: • Narrow • P. aeruginosa • A. baumannii • Resistance: uncommon • Formulations: • Colistin sulfate • Colistimethate sodium (CMS) • ColistinBase Activity (CBA) • 1mg CBA = 2.67mg CMS • ColistimethateSodium (CMS) • 1mg CMS = 12500 units CMS • Half-life: • CMS: 124 minutes • CBA: 251

  8. Dosing/Administration • HAP/VAP due to MDR GNB • Nebulized: 150mg CMS every 8 hours delivered over 60 minutes for 14 days* • Bronchodilator within 15 minutes prior to administration

  9. [1] Page 3

  10. Patient Qualifications • VAP due to GNB susceptible to AG or polymyxins • Not responding to IV antibiotics alone • HAP/VAP due to Acinetobacter sensitive only to polymyxins • HAP/VAP due to carbapenem-resistant pathogens

  11. IDSA/ATS HAP/VAP Guidelines Recommendations • VAP due to GNB susceptible to AG or polymyxins • IV + Inhaled • Compared: tobramycin, gentamicin, colistin • Organisms: • MDR Klebsiella pneumoniae • Pseudomonas aeruginosa • Acinetobacter baumannii • Improved clinical cure rate • No additional harmful effects • Reduced duration of mechanical ventilation

  12. IDSA/ATS HAP/VAP Guidelines Recommendations (continued) • HAP/VAP due to Acinetobacter sensitive only to polymyxins • IV Polymyxin+ Inhaled (adjunctive) • Higher clinical response • No increase in harm

  13. IDSA/ATS HAP/VAP Guidelines Recommendations (continued) • HAP/VAP due to carbapenem-resistant pathogens • IV Polymyxin+ Inhaled (adjunctive) • Potential pharmacokinetic advantage • Improved clinical outcomes • Improved mortality • No increase in harm • Routine antimicrobial susceptibility testing

  14. Summary • IV + Inhaled colistin • VAP due to GNB susceptible to AG or polymyxins • Not responding to IV antibiotics alone • HAP/VAP due to Acinetobacter sensitive only to polymyxins • HAP/VAP due to carbapenem-resistant pathogens • No differences in clinical response rates, mortality, or nephrotoxicity. • Exception: improved mortality in carbapenem-resistant pathogens • Reasonable component of empiric regimens in intensive care units with high rates of resistance to agents from other classes. • Over use of polymyxinsmay jeopardize its current role as the antibiotic of last resort for resistant gram-negative pathogens.

  15. References [1] Management of Patients with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Disease Society of American and the American Thoracic Society [2] Colistin: An overview, UpToDate. MacLaren, Spelman. March 14, 2017 [3] Colistimethate, Lexi-Drugs

  16. Questions?

More Related